Bottom line
NZUS vs XLV: the short answer
NZUS (State Street(R) SPDR(R) MSCI USA Climate Paris Aligned ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.
XLV is cheaper at 0.08% vs 0.1% — a difference of $2.00 a year per $10,000 invested.
Over one year, NZUS returned +24.3% vs +14.5% for XLV (reporting dates differ).
Updated Nov 19, 2026
NZUS vs XLV side by side
| NZUS | XLV | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | SPDR (State Street) |
| Category | Other | Health Care Sector |
| Expense ratio | 0.1% | 0.08% |
| Annual cost per $10k | $10 | $8 |
| 10-yr cost on $10k (prospectus) | $128 | $103 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0.02% |
| 1-yr return | +24.3% | +14.5% |
| 5-yr return (annualized) | — | +8.1% |
| 10-yr return (annualized) | — | +9.8% |
| Best quarter | +13.1% | +14.5% |
| Worst quarter | −4.2% | −12.7% |
| Net assets (fund) | — | $40.6B |
| Number of holdings | — | 65 |
| Portfolio turnover | 13% | 2% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | NZUS | XLV | Difference |
|---|---|---|---|
| 2024 | +24.3% | +2.5% | +21.8% |
| 2023 | +29.3% | +2.0% | +27.3% |
Source: Fund prospectus bar charts
Holdings overlap
NZUS and XLV share none of their top holdings.
NZUS top 10
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between NZUS and XLV?
NZUS (State Street(R) SPDR(R) MSCI USA Climate Paris Aligned ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs. XLV is cheaper at 0.08% vs 0.1% — a difference of $2.00 a year per $10,000 invested.
Which is cheaper, NZUS or XLV?
XLV has the lower expense ratio (0.08%).
Should I own both NZUS and XLV?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.